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Your responsibility
This guidance represents the view of NICE, arrived at after careful consideration of the evidence
available. When exercising their judgement, healthcare professionals are expected to take this
guidance fully into account. However, the guidance does not override the individual responsibility
of healthcare professionals to make decisions appropriate to the circumstances of the individual
patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local
context, in light of their duties to have due regard to the need to eliminate unlawful discrimination,
advance equality of opportunity, and foster good relations. Nothing in this guidance should be
interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable
health and care system and should assess and reduce the environmental impact of implementing
NICE recommendations wherever possible.
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1 Recommendations
NICE medical technologies guidance addresses specific technologies notified to NICE by
companies. The 'case for adoption' is based on the claimed advantages of introducing the
specific technology compared with current management of the condition. This case is
reviewed against the evidence submitted and expert advice. If the case for adopting the
technology is supported, then the technology has been found to offer advantages to patients
and the NHS. The specific recommendations on individual technologies are not intended to
limit use of other relevant technologies which may offer similar advantages.
1.1 The case for adopting the transurethral resection in saline (TURis) system for
resection of the prostate is supported by the evidence. Using bipolar diathermy
with TURis instead of a monopolar system avoids the risk of transurethral
resection syndrome and reduces the need for blood transfusion. It may also
reduce the length of hospital stay and hospital readmissions.
1.2 Using the transurethral resection in saline (TURis) system instead of monopolar
transurethral resection of the prostate (TURP) results in an estimated saving of
£71 per patient for hospitals that already use an Olympus monopolar system
and an estimated additional cost of £20 per patient for other hospitals.
However, there is some evidence of a reduction in readmissions with the TURis
system compared with monopolar TURP. If this evidence is included, using the
TURis system results in an estimated saving of £375 per patient for hospitals
that already use an Olympus monopolar system and an estimated saving of
£285 per patient for other hospitals.
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2 The technology
Description of the technology
2.1 Transurethral resection in saline (TURis, Olympus Medical) is a bipolar
electrosurgery system designed for use when surgical intervention is indicated
for prostatic enlargement.
2.2 The TURis system consists of an Olympus generator, a resectoscope, which
incorporates the TURis active working element and electrode, a telescope, an
inner and outer sheath, a light guide cable, and a saline cable. The active and
return electrode are contained within the resectoscope at the site of the
operation, eliminating the need for a patient return electrode because TURis
uses saline irrigation fluid to conduct electrical current within the resectoscope.
The surgeon uses an endoscopic image to guide the electrode assembly through
the urethra to the prostate. The electrode is then used to cut and coagulate
prostate tissue and saline is used to flush the bladder free of resected prostate
tissue and blood. Electrodes are available in different sizes and shapes
(described as loop, button and roller) for cutting or coagulation and to take into
account surgeon choice. Generally a loop is used to repeatedly cut out small
chippings to create a wide channel through the prostate and a roller or button
may be used to achieve haemostasis. The prostatic chippings are flushed out
before inserting a urethral urinary catheter at the end of the procedure.
2.3 The components of the TURis system are covered by individual CE marks. The
most recent of these was issued in 2013 for the TURis working element.
2.4 The list prices for the components of the TURis system for transurethral
resection of the prostate (excluding VAT) are:
£8905 for the resectoscope assembly (which includes the active working element,
telescope, inner and outer sheath, light guide cable and saline cable).
£14,681 for an ESG-400 Olympus generator.
Single-use roller and loop electrodes are £156.67 and £126.67 respectively. Each
TURis procedure uses 1 loop electrode and some procedures, typically 1 in 5, use an
additional roller electrode.
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The ESG-400 Olympus generator is usually provided at no cost as part of contractual
arrangements with Olympus to purchase electrodes at list price.
2.5 The claimed benefits of the TURis system for transurethral resection of the
prostate presented by the company were:
Reduced risk of transurethral resection syndrome through the use of saline irrigation
fluid.
Reduced risk of postoperative blood transfusion because of intraoperative bleeding.
A shorter length of stay in hospital due to a shorter surgical procedure and fewer intra-
and postoperative complications.
Earlier catheter removal time for improved patient comfort.
A quicker procedure compared with monopolar transurethral resection of the prostate
(TURP) so more men can be treated.
Fewer complications during and after surgery resulting in lower readmission rates.
Reduced costs (associated with postoperative blood transfusion,
healthcare-associated infection, length of hospital stay, postoperative irrigation and a
patient return electrode).
The use of saline irrigation fluid is cheaper and more readily available than glycine.
Current management
2.6 The NICE guideline on lower urinary tract symptoms defines benign prostate
enlargement as an increase in the size of the prostate gland because of benign
prostatic hyperplasia, and states that about 50% of men with benign prostatic
hyperplasia will develop benign prostatic enlargement. It recommends that
surgery is offered only if voiding lower urinary tract symptoms are severe or if
drug treatment and conservative management options have been unsuccessful
or are not appropriate.
2.7 For surgical treatment of benign prostatic enlargement, the NICE guideline on
lower urinary tract symptoms recommends the use of monopolar or bipolar
TURP, monopolar transurethral vaporisation of the prostate or holmium laser
enucleation of the prostate.
The TURis system for transurethral resection of the prostate (MTG23)
© NICE 2015. All rights reserved. Page 6 of 30
2.8 The NICE guideline on lower urinary tract symptoms also recommends some
alternative options:
Transurethral incision of the prostate (TUIP) can be offered as an alternative to other
types of surgery to men with a prostate estimated to be smaller than 30 g.
Open prostatectomy should only be offered as an alternative to other types of surgery
to men with prostates estimated to be larger than 80 g.
Other alternatives such as laser vaporisation techniques, bipolar transurethral
vaporisation of the prostate or monopolar or bipolar transurethral vaporisation
resection of the prostate should only be considered as part of a randomised controlled
trial that compares these techniques with TURP.
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3 Clinical evidence
Summary of clinical evidence
3.1 The key clinical outcomes for the transurethral resection in saline (TURis)
system for transurethral resection of the prostate presented in the decision
problem were:
hospital length of stay
procedural blood loss and blood transfusion
time to removal of urinary catheter postoperatively
transurethral resection syndrome
readmission for repeat procedures
duration of surgical procedure
healthcare-associated infection
quality of life
device-related adverse events.
3.2 The company identified a total of 1116 studies in their database searches, and
presented 24 studies in their submission as relevant to the decision problem.
These included 14 randomised trials, not all of which were published in full or in
English, with a total of 3032 patients (Abascal Junquera et al. 2006; Akman et al.
2013; Chen et al. 2009, 2010; Fagerstrom et al. 2010, 2011; Goh et al. 2009,
2010; Gulur et al. 2010a, 2010b; Michielsen et al. 2007, 2010a, 2010b; Rose
et al. 2007) and 10 observational studies (Bertolotto et al. 2009; Fumado et al.
2011; Giulianelli et al. 2012; Ho et al. 2007; Jun Hyun et al. 2012; Lee et al.
2011; Michielsen et al. 2010c, 2011; Petkov et al. 2011; Puppo et al. 2009).
3.3 The External Assessment Centre considered the 14 randomised trials described
in the submission. It established that the 3 randomised studies and
2 observational studies published by Michielsen reported on various stages and
subgroups of the same study population. It also considered that the 2 papers
from Fagerstrom were based on the same study population, and that the
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4 conference abstracts (Goh et al. 2009, 2010; Gulur et al. 2010a, 2010b) were
based on the same study population. Two studies were not published in English
but have English abstracts (Abascal Junquera et al. 2006; Rose et al. 2007). The
External Assessment Centre considered that, of these, only the Rose et al.
(2007) paper contained pivotal results and it obtained a translation of the paper;
the other was not considered pivotal. A literature search by the External
Assessment Centre identified 2 further randomised studies (Geavlete et al.
2011; Ho et al. 2006). In total the External Assessment Centre considered that
there were 10 unique randomised studies (1870 patients) relevant to the
decision problem, 9 published as papers (including 2 foreign language papers
with English abstracts) and 1 abstract.
3.4 The company presented 10 observational studies, 5 of which were published in
full and 5 of which were abstracts only. The External Assessment Centre
established that the Michielsen et al. (2010 and 2011) studies reported on
subgroups from the randomised study by Michielsen et al. published in 2007. A
literature search by the External Assessment Centre identified 1 additional
observational study (Shum et al. 2014). The External Assessment Centre
considered that there were 4 published papers and 5 abstracts describing
relevant observational studies. It agreed with the company's conclusion that the
outcomes reported from the observational studies were consistent with those
from the randomised trials. The observational studies are summarised in the
assessment report and are not considered further here.
Randomised trials: published papers
3.5 Akman et al. (2013) reported a Turkish study of 286 men (143 in each group)
randomised to have either TURis or monopolar transurethral resection of the
prostate (TURP) who were followed-up for 12 months. The mean procedure
duration was 54.0 minutes for TURis and 58.7 minutes for monopolar TURP,
p=0.03. The incidence of TUR syndrome was 0% for TURis and 1.5% for
monopolar TURP (no p value reported). There was no statistically significant
difference in the length of hospital stay for the TURis group compared with the
monopolar TURP group (2.5 days compared with 2.7 days, no p value reported).
The rate of blood transfusion was lower in the TURis group (2.4% compared
with 6.2%) but the difference was not statistically significant (p=0.2). There
were lower rates of clot retention (0.8% compared with 1.5%, p value not
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reported) and mean time to catheter removal (2.4 days compared with 2.6 days,
p value not reported) for TURis.
3.6 The Chen et al. (2009) study was done in China on 45 men with symptomatic
benign prostatic hypertrophy and a large prostate gland, randomised to have
either TURis or monopolar TURP. Results were analysed for 40 men, with
reasons given for withdrawals. The results showed that average procedure
duration was shorter in the TURis group compared with the monopolar TURP
group (88 minutes compared with 105 minutes, p=0.001). No men in the TURis
group had TUR syndrome, compared with a 5% rate (n=1/19) in the monopolar
TURP group. Fewer men had a blood transfusion in the TURis group (4.8%
compared with 15.5%, p value not reported). There was no statistically
significant difference between groups in the time to catheter removal (2.5 days
compared with 3.4 days, p=0.11). However there was a statistically significant
reduction in length of hospital stay for the TURis group (3 days compared with
4.2 days, p=0.001).
3.7 Chen et al. (2010) reported a separate study of 100 men in China randomised to
have either TURis or monopolar TURP. There was no statistically significant
difference in procedure duration in the TURis group compared with the
monopolar TURP group (59 minutes compared with 60 minutes, p=0.82) or
weight of tissue resected (40 g compared with 38.9 g, p=0.31). No patient in
either group had TUR syndrome. One man in the TURis group and 3 men in the
monopolar TURP group needed a blood transfusion (2% compared with 6%,
p=0.62).
3.8 The Fagerstrom et al. (2009 and 2011) studies were performed in Sweden on
202 men randomised to have either TURis or monopolar TURP. Results were
analysed for 185 men, with reasons given for withdrawals. Results showed that
there was no statistically significant difference between the TURis and
monopolar TURP group in mean procedure time (62 minutes compared with
66 minutes, p not significant) or weight of tissue resected (27.3 g compared with
26.3 g, p not significant). No patient developed TUR syndrome in the TURis
group, but 3 did so in the monopolar TURP group. A statistically significantly
lower proportion of men in the TURis group had a blood transfusion (4%
compared with 11%, p<0.01). Median time to catheter removal was the same in
both groups (20 hours), and the length of stay in hospital was similar (51 hours
compared with 52 hours). There was a statistically significant reduction in the
The TURis system for transurethral resection of the prostate (MTG23)
© NICE 2015. All rights reserved. Page 10 of 30
rate of readmission in the TURis group (n=5/98 compared with n=14/87,
p<0.011).
3.9 The Geavlete et al. (2011) study involved 510 men in Romania who were
randomised to 3 study arms (170 in each arm). Results are reported here for the
TURis and monopolar TURP arms (340 patients), but not for the bipolar plasma
vaporisation of the prostate arm which was considered to be outside the scope.
Statistical analysis was performed on the difference between the 3 groups and
is not reported here. The average procedure duration was 52.1 minutes in the
TURis group and 55.6 minutes in the monopolar TURP group. No men had TUR
syndrome in the TURis group compared with 3 men (1.8%) in the monopolar
TURP group. In the TURis group 3 men (1.8%) needed a blood transfusion,
compared with 11 men (6.5%) in the monopolar TURP group. In the TURis group
2 men (1.2%) had clot retention compared with 7 men (4.1%) in the monopolar
TURP group. The mean time to catheter removal was 46.3 hours (range
36–72 hours) in the TURis group compared with 72.8 hours (range
48–96 hours) in the monopolar TURP group. In the TURis group length of stay in
hospital was 3.1 days compared with 4.2 days in the monopolar TURP group.
3.10 The Ho et al. (2007) study was performed in Singapore on 48 men randomised
to TURis and 52 men randomised to monopolar TURP. There was no statistically
significant difference in mean procedure duration between the groups
(59 minutes for TURis compared with 58 minutes for monopolar TURP) or in the
weight of tissue resected (29.8 g TURis compared with 30.6 g monopolar TURP).
There was a statistically significantly lower rate of TUR syndrome in the TURis
group compared with the monopolar TURP group (0 men compared with 2 men,
p<0.005). One patient in each group needed a blood transfusion. In the TURis
group 3 men had clot retention compared with 2 men in the monopolar TURP
group; this difference was not statistically significant.
3.11 The Michielsen et al. (2007) study recruited patients between January 2005 and
June 2006 in Belgium. However, recruitment into the study continued until
August 2009, leading to subsequent papers reported as randomised (Michielsen
et al. 2010a, 2010b) and observational studies (Michielsen et al. 2010c, 2011).
In total 550 patients were included in the study; 285 in the TURis group and 265
in the monopolar TURP group, but some outcomes were reported on smaller
groups. There was no significant difference between the TURis group (n=263)
and monopolar TURP group (n=255) in mean procedure duration (52.1 minutes
The TURis system for transurethral resection of the prostate (MTG23)
© NICE 2015. All rights reserved. Page 11 of 30
compared with 50.9 minutes, p=0.357) or mean weight of tissue resected
(17.6 g compared with 19.2 g, p=0.173). TUR syndrome did not occur in the
TURis group and occurred twice (0.8%) in the monopolar TURP group (p value
not reported). In the TURis group (n=118) 4 men (3.4%) needed a blood
transfusion compared with 1 patient (0.8%) in the monopolar TURP group
(n=120, p=0.211). There was no statistically significant difference in mean
length of hospital stay: 3.72 days in the TURis group (n=263) and 3.89 days in
the monopolar TURP group (n=255, p=0.773). No patients in the TURis group
(n=118) and 2 patients in the monopolar TURP group (n=120) needed a repeat
procedure because of incomplete resection (p value not reported).
3.12 The Rose et al. (2007) study was published in German and the External
Assessment Centre obtained an English translation. It included 38 men who had
TURis and 34 men who had monopolar TURP (the remainder had treatment for
bladder cancer) in Germany. Mean procedure duration was longer in the TURis
group than in the monopolar TURP group (55 minutes compared with
35 minutes, p=0.005), but the mean weight of tissue resected tended to be
greater in the TURis group (42 g compared with 31 g, p value not reported). No
men had TUR syndrome in either group. The mean time to catheter removal was
longer in the TURis group (64 hours compared with 49 hours, p value not
reported) and the TURis group had a higher rate of readmission because of
haemorrhage (n=4/38 compared with n=1/34, p value not reported).
3.13 The Abascal Junquera et al. (2006) study was published in Spanish with an
English abstract that had limited information on the statistical analysis. The
External Assessment Centre considered that the study did not provide
additional important data and the paper was therefore not translated. In this
study 45 men were prospectively randomised, with 24 men having TURis and
21 men having a TURP procedure using a monopolar system. TURis was a
slightly quicker procedure compared with monopolar TURP (39.7 minutes
compared with 42.7 minutes) based on a similar resection weight (13 g for
TURis compared with 12.6 g for monopolar TURP). The time to removal of the
catheter was similar between the groups (2.92 days for TURis compared with
3.1 days for monopolar TURP, not statistically significant) as was the length of
hospital stay (3.63 days for TURis compared with 3.67 days for monopolar
TURP).
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Randomised trials: abstracts
3.14 The Goh et al. (2009 and 2010); and Gulur et al. (2010a and 2010b) conference
abstracts relate to the same multicentre study (country not reported). In this
study, 210 men with benign prostatic obstruction were randomly allocated to
TURis (n=110) or monopolar TURP (n=100). The study reported a similar
procedure duration for TURis compared with monopolar TURP (38 minutes
compared with 35 minutes, not statistically significant). There were no cases of
TUR syndrome in the TURis group and 3 (3%) in the monopolar TURP group
(p value not reported). Men in the TURis group tended to have a shorter time to
catheter removal (48 hours compared with 52 hours, p=0.97), and a shorter
hospital stay (90 hours compared with 103 hours, p=0.06) but neither result
was statistically significant.
Meta-analysis of evidence
3.15 The company presented fixed-effect meta-analyses of the randomised studies
for procedure-related outcomes between TURis and monopolar TURP for TUR
syndrome, clot retention, procedure duration, time to catheter removal, length
of hospital stay and procedural blood loss. The results are described in
sections 3.17–3.22 with further details in the assessment report on pages
81–98. A summary of the results is presented in table 1.
3.16 The External Assessment Centre did not agree with the included studies used
for some outcomes in the company meta-analyses. It did revised meta-analyses
with changes in the selected studies, investigated additional outcomes and
explored using either fixed- or random-effects methods. The results of the
External Assessment Centre revised meta-analyses are shown in table 1.
Table 1 Results of company's meta-analyses and the External Assessment Centre
revised meta-analyses (all fixed effects)
Outcome Company's meta-analysis External Assessment Centre's revised
meta-analysis
Studies
(n)
Relative risk for
TURis (95% CI)
Studies
(company
studies)
Relative risk for
TURis (95% CI)
TUR syndrome 6 0.28 (0.08 to 1.02) 6 (2) 0.18 (0.05 to 0.62)
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Blood transfusion 3 0.36 (0.16 to 0.80) 6 (3) 0.35 (0.19 to 0.65)
Clot retention 2 0.63 (0.21 to 1.90) 5 (2) 0.55 (0.26 to 1.15)
Studies
(n)
Mean difference for
TURis (95% CI)
Studies Mean difference for
TURis (95% CI)
Hospital stay (days) 3 −0.52 (−0.74 to
−0.30)
2 (2) −0.19 (−0.46 to 0.07)
Time to removal of
catheter (days)
3 −0.23 (−0.38 to
−0.08)
2 (2) −0.09 (−0.25 to 0.06)
Procedure time
(minutes)
4 −1.68 (−4.18 to 0.81) 5 (4) −1.36 (−3.70 to 0.98)
CI, confidence interval; TURis, transurethral resection in saline; TUR, transurethral resection.
3.17 The company included 6 studies presenting results assessing the risk of TUR
syndrome (Abascal Junquera et al. 2006; Akman et al. 2013; Chen et al. 2010;
Goh et al. 2010; Michielsen et al. 2011; Rose et al. 2007). The company applied a
continuity correction to account for the zero event rate in all TURis arms,
replacing nil values with 0.5. They found a non-statistically significant lower
pooled relative risk in favour of TURis of 0.28 (95% confidence interval [CI]
0.08 to 1.02). The External Assessment Centre repeated the company's
meta-analysis, excluding 4 studies: 3 studies in which there were no cases of
TUR syndrome in either arm, and the results from the conference abstract by
Goh et al. (2010). The External Assessment Centre added data from
4 randomised studies that the company did not include (Ho et al. 2006; Chen
et al. 2009; Fagerstrom et al. 2011; Geavlete et al. 2011). This revised
meta-analysis found a statistically significant effect in favour of TURis: relative
risk 0.18 (95% CI 0.05 to 0.62, p=0.006), corresponding to a number needed to
treat to prevent 1 case of TUR syndrome compared with monopolar
TURP of 50.
3.18 The company's meta-analysis of trials presenting data on blood transfusion gave
a pooled relative risk of 0.52 (95% CI 0.26 to 1.04) in favour of TURis based on
4 studies (Akman et al. 2013; Chen et al. 2010; Fagerstrom et al. 2011;
Michielsen et al. 2007). The company re-ran this analysis, excluding Michielsen
et al. (2007) because a higher proportion of procedures were carried out by
trainee surgeons in the TURis arm of that study. This gave a pooled relative risk
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of 0.36 (95% CI 0.16 to 0.80) in favour of TURis. The External Assessment
Centre agreed with this approach and repeated the analysis, adding data from
3 further studies (Chen et al. 2009; Ho et al. 2006; Geavlete et al. 2011). The
result was a statistically significant effect in favour of TURis with a relative risk
of 0.35 (95% CI 0.19 to 0.65, p=0.0008). The External Assessment Centre
calculated the number needed to treat to prevent 1 case of blood transfusion
compared with monopolar TURP) as 20.
3.19 For clot retention, the company's meta-analysis included 2 studies (Akman et al.
2013; Michielsen et al. 2007) and found a relative risk in favour of TURis of 0.63
(95% CI 0.21 to 1.90; not statistically significant). The External Assessment
Centre re-ran the meta-analysis adding 3 further studies (Chen et al. 2010;
Geavlete et al. 2011; Ho et al. 2006) giving a revised pooled relative risk of 0.55
(95% CI 0.26 to 1.15, p=0.11).
3.20 For length of hospital stay, the company conducted a meta-analysis on 3 trials
presenting data on length of hospital stay (Akman et al. 2013; Chen et al. 2009;
Michielsen et al. 2011) which revealed a pooled mean difference between the
groups (TURis minus monopolar TURP) of −0.52 days (95% CI −0.74 to −0.30,
p=0.0001). The External Assessment Centre examined the impact of the study
by Chen et al. (2009), which was a source of significant heterogeneity and
considered that it should be excluded. The External Assessment Centre
calculated a pooled mean difference in length of hospital stay between the
groups (TURis minus monopolar TURP) of −0.19 days (95% CI −0.46 to 0.07,
p=0.16) which was not statistically significant.
3.21 The company included 3 randomised studies (Akman et al. 2013; Chen et al.
2009, Michielsen et al. 2010) in its analysis of mean time to removal of the
urinary catheter and reported a significantly shorter time in favour of TURis of
−0.23 days (95% CI −0.38 to −0.08). The External Assessment Centre excluded
the Chen et al. (2009) study because it introduced significant heterogeneity to
the analysis and presented a result based on 2 studies (Akman et al. 2013;
Michielsen et al. 2010) which gave a non-statistically significant pooled mean
difference (TURis minus monopolar TURP) for time to catheter removal of
−0.09 days (95% CI −0.25 to 0.06).
3.22 The company's meta-analysis of trials presenting data for procedure duration
included 4 papers (Akman et al. 2013; Chen et al. 2010; Fagerstrom et al. 2011;
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Michielsen et al. 2010), and found a non-significant mean difference (TURis
minus monopolar TURP) of −1.68 minutes (95% CI −4.18 to 0.81). The External
Assessment Centre agreed with the exclusion of Michielsen et al. (2007) in the
company's initial analysis but considered the addition of 2 further studies (Chen
et al. 2009; Ho et al. 2006). After the External Assessment Centre explored the
heterogeneity of the meta-analysis calculations, it presented a result based on
5 studies, which gave a non-statistically significant pooled mean difference in
procedure time in favour of TURis of −1.36 minutes (95% CI −3.70 to 0.98,
p=0.26).
3.23 The External Assessment Centre examined 3 further outcomes that were not
included in the company's meta-analysis. For readmission because of
haemorrhage, data from 3 randomised studies were used (Fagerstrom et al.
2011; Geavlete et al. 2011; Rose et al. 2007) and the result was a
non-statistically significant lower rate for TURis, with a relative risk of
0.53 (95% CI 0.22 to 1.25, p=0.15). The External Assessment Centre also
conducted a meta-analysis on urethral strictures and bladder neck contractures
because this was highlighted as a potential concern with TURis by expert
advisers. This analysis included 5 studies (Ackman et al. 2013; Chen et al. 2010;
Fagerstrom et al. 2011; Geavlete et al. 2011; Michielsen et al. 2011) and found
no statistically significant difference between the groups, with a relative risk of
1.08 (95% CI 0.70 to 1.69, p=0.72). The third additional outcome considered by
the External Assessment Centre was repeat procedure because of incomplete
resection. This analysis included 3 studies (Fagerstrom et al. 2011; Geavlete
et al. 2011; Michielsen et al. 2011) and found no statistically significant
difference between the groups: relative risk 0.76 (95% CI 0.42 to 1.40, p=0.38).
Committee considerations
3.24 The Committee considered that the evidence demonstrated the clinical
equivalence of TURis and monopolar TURP for prostatic resection. The
Committee noted there was evidence showing that the TURis system reduces
the risk of TUR syndrome and reduces patients' need for blood transfusion as
compared with monopolar TURP.
3.25 The Committee considered length of hospital stay derived from the
meta-analyses by the company and by the External Assessment Centre. It
discussed the rationale for excluding the Chen et al. (2009) study. The External
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Assessment Centre confirmed that it excluded the Chen et al. (2009) study
because it was the source of significant heterogeneity in the meta-analysis
results. However, the External Assessment Centre stated that it did not differ in
terms of methodological quality from the 2 included studies. The Committee
noted that all the trials were based outside the UK and heard expert advice that
local policies on healthcare reimbursement and hospital-specific catheter
guidelines could have an effect on length of hospital stay. The Committee
concluded that there was a possibility that TURis would result in shorter
hospital stays, but that clinical trial data were inconclusive.
3.26 The Committee discussed readmission to hospital after resection and noted
that this outcome was not included in most of the clinical trials. However, it
noted a non-statistically significant lower rate of readmission because of
bleeding for TURis compared with monopolar TURP in the data from 3 trials
included in a meta-analysis. The Committee also noted that the readmission
rate reported in the Fagerstrom et al. (2011) study showed a statistically
significant reduction in the TURis group compared with the monopolar TURP
group (n=5/98 compared with n=14/87, p<0.011). In addition, it heard expert
advice based on experience of the use of TURis in the NHS, which suggested
that there was indeed a reduction in readmissions due to bleeding seen in
clinical practice. Based on the evidence, the Committee concluded that it was
plausible that TURis would result in lower readmission rates, although the
evidence was not definitive.
3.27 The Committee considered the other outcomes from the meta-analysis and
noted no statistically significant differences between TURis and monopolar
TURP in procedure time, time to catheter removal, the incidence of clot
retention and incidence of urethral stricture or bladder neck contracture.
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4 NHS considerations
System impact
4.1 The company proposed that using the transurethral resection in saline (TURis)
system would not result in changes to the current pathway or involve additional
system resources. The External Assessment Centre agreed with these
assumptions.
4.2 The company and the External Assessment Centre did not identify any special
additional training needs for a switch to the TURis system from monopolar
transurethral resection of the prostate (TURP). The Committee received expert
advice that confirmed that little training is needed for surgeons who are already
performing monopolar TURP procedures.
Committee considerations
4.3 Based on the evidence from the company and the External Assessment Centre
and on expert advice, the Committee was satisfied that using the TURis system
could produce benefits for patients and for the NHS and would be relatively
easy to introduce, with minimal additional training requirements.
4.4 The Committee noted that the costs of adopting the TURis system were
different depending on whether hospitals were already using Olympus systems.
The company stated that 40–45% of UK hospitals would already have access to
a component of the Olympus systems. The Committee concluded that it was
important to consider both scenarios in the cost analysis.
4.5 For hospitals that currently use monopolar equipment for TURP, expert advice
to the Committee was that most would wish to change to bipolar systems when
their monopolar equipment needs replacing.
4.6 The Committee noted the advice that surgeons who are already skilled at
performing TURP with monopolar equipment would need very little training to
use the TURis system. It concluded that additional training would not be a
significant consideration in the adoption of this technology.
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5 Cost considerations
Cost evidence
5.1 The company presented 3 published economic studies on surgical procedures
for prostate enlargement, 2 of which reported costs for bipolar transurethral
resection of the prostate (TURP) compared with monopolar TURP. The External
Assessment Centre identified 1 other observational study. The studies came
from different healthcare systems (Japan, India and Singapore) where care
pathways vary from those in the NHS. In addition, it was not clear whether
patients had received treatment with the transurethral resection in saline
(TURis) system and the studies did not directly compare monopolar and bipolar
systems. The economic studies are summarised in the assessment report and
are not considered further here.
5.2 The company submitted a de novo cost analysis comparing the cost
consequences of procedures using the TURis system and a monopolar TURP
system. The time horizon of the model was a non-defined short time period
designed to capture procedure-related complications. Costs were modelled
from an NHS perspective and a discount rate of 3.5% per year was applied. The
population included in the model was men having surgical intervention for
prostate enlargement. The model adopted a cost-minimisation approach based
on an assumption of no difference in the efficacy of TURis and monopolar TURP
in terms of resection weight or completeness of resection. The model included
the cumulative costs associated with the initial surgical procedure,
complications resulting from the procedure and the need for reoperation or
readmission. The sensitivity analysis also included clot retention and the need
for reoperation in the event that the initial procedure was stopped before
completion.
5.3 The company's model contained 3 clinical parameters: length of hospital stay,
rate of blood transfusion and rate of TUR syndrome. The company used
0.52 days (95% CI 0.30 to 0.74) for reduction in the length of hospital stay, from
a meta-analysis of 3 studies. The reduction in the rate of blood transfusion was
taken as 0.36 (95% CI 0.16 to 0.80) from a meta-analysis of 3 studies. The rate of
TUR syndrome was taken as zero for TURis patients and 1.14% (95% CI
0.30 to 1.98) for monopolar TURP from a meta-analysis of 6 studies. Full details
are in section 9.4.3 of the company's submission.
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5.4 The equipment costs for the TURis system included capital costs and the
consumable costs of the electrodes. The Olympus generator was assumed to be
provided without cost. It was assumed that each hospital would need
3 complete TURis systems. The capital costs differed between hospitals that
used Olympus monopolar TURP systems and those that did not since some of
the components are interchangeable. The company took these costs from
Olympus data on file. For hospitals with Olympus monopolar systems, the cost
of purchasing a TURis system included 3 working elements and 3 saline cables
at a cost of £8800. Hospitals not using Olympus equipment would additionally
need 3 each of the following: a telescope, an inner sheath, an outer sheath and a
light guide cable at a total cost of £26,715. These capital elements were
assumed to have a mean working life of 7 years at 150 procedures a year. This
resulted in a capital cost per patient of £9.68 for hospitals using Olympus
systems and £29.13 for other hospitals.
5.5 The estimated cost of electrodes for each TURis procedure was based on
1 single-use loop electrode and in 22% of procedures an additional single-use
roller electrode.
5.6 For monopolar TURP the company assumed that hospitals have an existing
system and so capital costs were not considered. The cost of electrodes for a
monopolar TURP procedure was estimated to be 50% of the TURis electrode
costs; this came to £80.57 per procedure.
5.7 The company included a £1848 cost for TUR syndrome, assuming an additional
2 days in a high-dependency unit and 2 days in a general ward. The company
based the cost of a blood transfusion on an estimate used in a study by Varney
et al. (2003), which was £920.40.
5.8 The results of the company's base case stated that the average total cost per
patient of using the TURis system was £1043.57 for hospitals using Olympus
systems and £1063.01 for hospitals not using Olympus systems, compared with
£1177.20 for a monopolar TURP system. TURis therefore reduced costs for
hospitals using Olympus systems by £133.63 per procedure and for hospitals
not using Olympus systems by £114.19 per procedure.
5.9 The results of one-way probabilistic and threshold analyses done by the
company suggested that these results were robust. The key drivers of the
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savings in the company's cost model were the reduction in the length of hospital
stay and the cost of monopolar consumables.
5.10 The External Assessment Centre considered the company's basic model
structure to be appropriate. The External Assessment Centre revised the cost
model parameters based on its meta-analyses results and so used a zero
difference in the length of hospital stay between TURis and monopolar TURP; a
relative risk of blood transfusion for TURis compared with monopolar TURP of
0.35; and a relative risk of TUR syndrome for TURis compared with monopolar
TURP of 0.18.
5.11 The External Assessment Centre considered that the company's costs for blood
transfusion overestimated the true costs because several components were
included that would not typically be needed. The External Assessment Centre
estimated the cost of a blood transfusion to be £329, based on the cost of
2.7 units of red blood cells.
5.12 The External Assessment Centre could not find a rationale for the company's
assumption that the cost of monopolar electrodes was 50% of the cost of the
TURis electrode. Based on advice from the clinical experts, the External
Assessment Centre assumed that all monopolar TURP procedures, in both
Olympus and non-Olympus cases, involved both a loop and a roller electrode.
The External Assessment Centre considered that hospitals using Olympus
systems obtained the generator on loan and paid the list price for monopolar
TURP consumables (£137.75). Hospitals not using Olympus systems have the
option to purchase a non-Olympus electrosurgery unit generator, incurring a
higher initial cost but allowing the purchase of monopolar electrodes at a lower
price from NHS Supply Chain, saving money over the lifetime of the
electrosurgery unit. The External Assessment Centre used a price of £66.84 for
hospitals not using Olympus systems (based on the price of generic monopolar
TURP consumables [£56.84] from NHS Supply Chain and a £10 per procedure
electrosurgery unit cost).
5.13 The results for the base case in the External Assessment Centre's revised model
found a total cost per TURis procedure in hospitals using Olympus systems of
£1183.99 and in other hospitals of £1203.44. The total costs for a monopolar
TURP were £1196.60 for hospitals using Olympus systems and £1125.69 for
other hospitals. TURis was cost saving for hospitals using Olympus systems by
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£12.60, but added costs of £77.75 for other hospitals. The savings are driven by
a reduction in risk of TUR syndrome and blood transfusion.
5.14 The External Assessment Centre reported an additional scenario involving
readmissions for all causes, based on data from the Fagerstrom et al. (2011)
study. The rate of readmission (all causes) for TURis was 5.1% and for
monopolar TURP was 16.1%, giving a relative risk for TURis of 0.31, p=0.011.
The External Assessment Centre estimated the cost of a readmission (all causes)
as £2781, based on the NHS reference cost 2012/13 code LB20D. Results
obtained when readmission from all causes was included in the model revealed
that TURis saved £319.62 per procedure for a hospital with an existing Olympus
monopolar TURP system and £229.27 per procedure for other hospitals.
5.15 The External Assessment Centre calculated a further revision to the model at
the request of the Committee, with a change to the mean difference in hospital
stay from zero to 0.19 days in favour of TURis, based on the External
Assessment Centre's meta-analysis. The results for the recalculated base case in
the External Assessment Centre's revised model found a total cost per TURis
procedure in Olympus centres of £1126.04 and in non-Olympus centres of
£1145.49. The total costs for a monopolar TURP were £1196.60 for a hospital
using Olympus systems and £1125.69 for other hospitals. TURis was cost saving
for a hospital using Olympus systems by £70.55, but added costs of £19.80 for
other hospitals.
5.16 The External Assessment Centre calculated a revised result based on the
meta-analysis results for the reduction in readmissions associated with TURis,
including data from the Fagerstrom et al. (2011) study at the request of the
Committee. The results showed TURis was cost saving by £375.02 per
procedure for a hospital with an existing Olympus monopolar TURP system and
by £284.66 for other hospitals.
Committee considerations
5.17 The Committee agreed with the External Assessment Centre's conclusions that
the published economic studies did not contain relevant evidence. It also agreed
with the revisions suggested by the External Assessment Centre in terms of the
costs of the consumables and blood transfusion costs. It heard expert opinion
that patients having a blood transfusion may also have an increased length of
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stay in hospital and it noted that this was not included in the model. The
Committee considered it was quite likely that TURis could be cost saving, but
noted the uncertainties in the External Assessment Centre and company
meta-analyses for length of hospital stay. At the draft guidance meeting the
Committee considered that the cost model should include the 0.19 days
difference in the length of hospital stay in favour of TURis compared with
monopolar TURP. Results from the revised model showed that TURis saved
around £71 per patient for hospitals that already use Olympus systems and has
an additional cost of around £20 per patient for other hospitals (see
section 5.15). The Committee concluded that, although uncertainty remained in
the cost model, the use of the TURis system is likely to generate cost savings
compared with the monopolar TURP system.
5.18 The Committee noted that the data available to estimate differences in
readmission rates between TURis and monopolar TURP were limited in
quantity, but it received expert advice that a reduction in readmissions was
likely if TURis was used, instead of monopolar TURP. From the results of the
External Assessment Centre's scenario analysis based on the Fagerstrom et al.
(2011) study it considered that it was plausible there would be cost savings for
hospitals with TURis, attributable to fewer readmissions, whether or not the
hospitals were already using Olympus equipment.
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6 Conclusions
6.1 The Committee concluded that the evidence demonstrated that the
transurethral resection in saline (TURis) system was of equivalent efficacy to
the monopolar system for transurethral resection of the prostate (TURP). It
noted the important clinical advantages of TURis are reducing the risk of TUR
syndrome that exists with monopolar TURP and reducing the need for blood
transfusion. The Committee considered that it is plausible that TURis will also
reduce length of hospital stay and reduce readmissions after surgery, although
the evidence on these outcomes was limited.
6.2 The Committee accepted the External Assessment Centre revised model and
sensitivity analyses and judged that, although uncertainty remained in the cost
model, the use of the TURis system is likely to generate cost savings compared
with the monopolar TURP system. It acknowledged that cost savings would be
easier to achieve in hospitals that currently use Olympus monopolar systems.
The Committee concluded that the case for adoption of the TURis system for
transurethral resection of the prostate was supported by the evidence.
Andrew Dillon
Chief Executive
February 2015
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8 Sources of evidence considered by the Committee
The External Assessment Centre report for this assessment was prepared by Cedar:
Cleves A, Morgan H, Poole R et al. The TURis system for transurethral resection of the
prostate, June 2014
Submissions from the following company:
Olympus Medical
The following individuals gave their expert personal view on The TURis system for transurethral
resection of the prostate by providing their expert comments on the draft scope and assessment
report.
Mr Neil Barber, British Association of Urological Surgeons (BAUS) – clinical expert
Mr Andrew Dickinson, British Association of Urological Surgeons (BAUS) – clinical expert
Mr John McGrath, British Association of Urological Surgeons (BAUS) – clinical expert
Mr Ian Pearce, British Association of Urological Surgeons (BAUS) – clinical expert
Mr Mark Speakman, British Association of Urological Surgeons (BAUS) – clinical expert
The following individuals gave their expert personal view on the TURis system for transurethral
resection of the prostate in writing by completing a patient questionnaire or expert adviser
questionnaire provided to the Committee.
Mr Neil Barber, British Association of Urological Surgeons (BAUS) – clinical expert
Mr Andrew Dickinson, British Association of Urological Surgeons (BAUS) – clinical expert
Mr John McGrath, British Association of Urological Surgeons (BAUS) –clinical expert
Mr Ian Pearce, British Association of Urological Surgeons (BAUS) – clinical expert
Mr Mark Speakman, British Association of Urological Surgeons (BAUS) – clinical expert
Hannah Winter, Prostate Cancer UK – patient expert
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About this guidance
This guidance was developed using the NICE medical technologies guidance process.
It has been incorporated into the NICE pathway on lower urinary tract symptoms in men, along
with other related guidance and products.
We have produced a summary of this guidance for the public. Tools to help you put the guidance
into practice and information about the evidence it is based on are also available.
Related NICE guidance
For related NICE guidance, please see the NICE website.
Your responsibility
This guidance represents the views of NICE and was arrived at after careful consideration of the
evidence available. Healthcare professionals are expected to take it fully into account when
exercising their clinical judgement. However, the guidance does not override the individual
responsibility of healthcare professionals to make decisions appropriate to the circumstances of
the individual patient, in consultation with the patient and/or guardian or carer.
Implementation of this guidance is the responsibility of local commissioners and/or providers.
Commissioners and providers are reminded that it is their responsibility to implement the
guidance, in their local context, in light of their duties to have due regard to the need to eliminate
unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this
guidance should be interpreted in a way which would be inconsistent with compliance with those
duties.
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